Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia.
Level 4 - case-series / case-control
Retrospective cross-sectional comparative study
PubMed 35289513 · doi:10.20945/2359-3997000000437
What was done
Retrospective clinical record review of 131 Portuguese females (32 girls aged 3–9 years and 99 adolescents and premenopausal women aged 13–49 years) evaluated for suspected non-classic congenital adrenal hyperplasia (NC-CAH). Participants underwent complete CYP21A2 molecular analysis and were stratified into three groups: NC-CAH (n = 46), heterozygous pathogenic variant carriers (n = 49), and wild type (n = 36). Clinical signs, symptoms, and basal and post-cosyntropin stimulated 17-hydroxyprogesterone (17OHP) concentrations measured by electrochemiluminescence immunoassay were compared across groups.
What was found
Clinical features did not significantly differ between groups. Heterozygous carriers demonstrated significantly higher basal and post-cosyntropin 17OHP levels compared to wild-type individuals (p < 0.05) and significantly lower levels compared to NC-CAH patients (p < 0.05). However, there was substantial overlap in 17OHP values among the three groups. The most frequently identified pathogenic variant was p.Val282Leu. Exact numerical hormonal concentrations, variances, and diagnostic test parameters were not reported in the abstract.
Why it matters
Confirms that although CYP21A2 heterozygosity produces an intermediate biochemical phenotype, standard basal and cosyntropin-stimulated 17OHP measurements cannot reliably rule in or rule out carrier status, establishing molecular testing as the only sensitive diagnostic method.
Limits
Retrospective design conducted exclusively in a Portuguese cohort referred for suspected NC-CAH, limiting generalizability to broader or asymptomatic populations. The abstract omits numerical values, confidence intervals, and sensitivity/specificity thresholds for the biochemical assays.
Cited by
- supports Carrying two copies of a genetic mutation causing adrenal androgen overproduction (such as non-classical congenital adrenal hyperplasia) can cause infertility, whereas heterozygosity (carrying one copy) causes androgen overproduction without causing infertility.